A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Apyx Medical Corp
APYX
$163M
Mkt Cap
$3.92
+2.35%
Apyx Medical Corp (APYX) has a 5-year average return on invested capital (ROIC) of -36.3%. This is below average and may indicate limited pricing power.
Apyx Medical Corp (APYX) has a market capitalization of $164M. It is classified as a small-cap stock.
Apyx Medical Corp (APYX) does not currently pay a regular dividend.
Apyx Medical Corp (APYX) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Apyx Medical Corp (APYX) reported annual revenue of $53 million in its most recent fiscal year, based on SEC EDGAR filings.
Apyx Medical Corp (APYX) has a net profit margin of -21.2%. The company is currently unprofitable.
Apyx Medical Corp (APYX) generated $-9 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Apyx Medical Corporation (“Company”, “Apyx Medical”, “we”, “us”, or “our”) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760. We are a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring SystemTM (“AYON”) in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. AYON is an FDA-cleared, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 56M | 53M | 48M | 52M | 45M | 49M |
| Net Income | -9.2M | -11M | -23M | -19M | -23M | -15M |
| EPS | $-0.23 | $-0.27 | $-0.66 | $-0.54 | $-0.67 | $-0.44 |
| Free Cash Flow | -9.0M | -9.1M | -19M | -5.8M | -21M | -11M |
| ROIC | -20.2% | -23.0% | -43.5% | -38.4% | -50.8% | -25.8% |
| Gross Margin | 63.2% | 62.5% | 61.0% | 64.5% | 65.4% | 69.3% |
| Debt/Equity | 2.74 | 2.70 | 2.73 | 1.44 | 0.02 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -4.3M | -6.4M | -19M | -17M | -24M | -14M |
| Operating Margin | -7.7% | -12.2% | -39.2% | -33.0% | -52.9% | -29.8% |
| ROE | -71.5% | -78.0% | -114.7% | -58.2% | -50.8% | -25.8% |
| Shares Outstanding | 42M | 42M | 36M | 35M | 35M | 34M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 28M | 30M | 8.8M | 10M | N/A | 28M | 28M | 49M | 45M | 52M | 48M | 53M | 56M |
| Gross Margin | 32.5% | 42.5% | 58.0% | 68.0% | N/A | 67.6% | 63.2% | 69.3% | 65.4% | 64.5% | 61.0% | 62.5% | 63.2% |
| R&D | 1.4M | 2.2M | 1.0M | 1.9M | 2.5M | 3.7M | 3.9M | 4.3M | 4.5M | 5.4M | 5.1M | 3.4M | 3.3M |
| SG&A | 6.7M | 8.4M | 6.2M | 8.7M | 9.4M | 14M | 12M | 19M | 20M | 22M | 19M | 16M | 16M |
| EBIT | -5.8M | -7.0M | -11M | -14M | -14M | -21M | -20M | -14M | -24M | -17M | -19M | -6.4M | -4.3M |
| Op. Margin | -21.1% | -23.7% | -129.2% | -135.7% | N/A | -73.9% | -72.5% | -29.8% | -52.9% | -33.0% | -39.2% | -12.2% | -7.7% |
| Net Income | -18M | 8.4M | -4.0M | -5.1M | 63M | -20M | -12M | -15M | -23M | -19M | -23M | -11M | -9.2M |
| Net Margin | -65.8% | 28.3% | -44.8% | -49.5% | N/A | -69.8% | -42.9% | -31.3% | -52.1% | -35.7% | -48.8% | -21.2% | -16.4% |
| Non-Recurring | 719K | 136K | 157K | 2.0M | 741K | -89K | 387K | -48K | -75K | 3.1M | 150K | 322K | 322K |
| Returns on Capital | |||||||||||||
| ROIC | -18.6% | 67.8% | -14.3% | -19.0% | 112.3% | -24.8% | -17.6% | -25.8% | -50.8% | -38.4% | -43.5% | -23.0% | -20.2% |
| ROE | -177.0% | 67.2% | -15.9% | -21.0% | 114.9% | -24.9% | -17.6% | -25.8% | -50.8% | -58.2% | -114.7% | -78.0% | -71.5% |
| ROA | -62.8% | 29.7% | -11.9% | -15.3% | 98.8% | -21.8% | -15.0% | -21.2% | -38.5% | -28.6% | -32.6% | -17.0% | -14.5% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -417K | -5.8M | -2.8M | -3.7M | 21M | -18M | -16M | -10M | -20M | -5.2M | -18M | -8.0M | -7.9M |
| Free Cash Flow | -1.0M | -6.2M | -3.1M | -4.3M | 21M | -20M | -17M | -11M | -21M | -5.8M | -19M | -9.1M | -9.0M |
| Owner Earnings | -1.7M | -7.2M | -4.4M | -5.3M | 18M | -23M | -21M | -16M | -28M | -11M | -23M | -11M | -10M |
| CapEx | 630K | 421K | 286K | 624K | 363K | 1.3M | 581K | 723K | 1.0M | 533K | 722K | 1.1M | 1.1M |
| Maint. CapEx | 876K | 812K | 734K | 696K | 669K | 754K | 887K | 903K | 890K | 692K | 599K | 655K | 719K |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 547K | 0 | 0 | 120K | 0 | 123K | 459K | 400K |
| D&A | 876K | 812K | 734K | 696K | 669K | 754K | 887K | 903K | 890K | 692K | 599K | 655K | 719K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 388K | 575K | 809K | 871K | 2.2M | 3.6M | 4.2M | 5.1M | 6.7M | 5.1M | 4.0M | 2.0M | 1.9M |
| Debt Repayment | 3.2M | 239K | 240K | 239K | 2.7M | 0 | 0 | 0 | 0 | 11M | 11K | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -8.9M | -8.6M | -12M | -7.3M | -78M | -114M | -81M | -31M | -9.5M | -5.2M | 7.0M | 7.6M | 4.0M |
| Cash & Equiv. | 5.7M | 12M | 14M | 9.9M | 17M | 59M | 42M | 31M | 10M | 44M | 32M | 32M | 31M |
| Long-Term Debt | -3.2M | 2.9M | 2.7M | 2.5M | 0 | 421K | 183K | 18K | 0 | 33M | 34M | 35M | 35M |
| Debt/Equity | -2.11 | 0.14 | 0.11 | 0.12 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 1.44 | 2.73 | 2.70 | 2.74 |
| Interest Coverage | -38.7 | -44.2 | -72.1 | -102.1 | -137.3 | -2608.6 | -436.6 | -1444.8 | -1570.8 | -7.0 | -3.2 | -1.2 | -1.2 |
| Equity | 1.5M | 23M | 26M | 22M | 87M | 71M | 64M | 54M | 38M | 27M | 14M | 15M | 13M |
| Total Assets | 25M | 31M | 35M | 31M | 96M | 85M | 74M | 69M | 52M | 79M | 65M | 67M | 63M |
| Total Liabilities | 20M | 8.0M | 8.9M | 9.0M | 8.8M | 13M | 10M | 15M | 14M | 52M | 51M | 52M | 50M |
| Intangibles | 431K | 323K | 215K | 67K | 6K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -28M | -19M | -23M | -28M | 34M | 15M | 2.6M | -13M | -36M | -54M | -78M | -89M | -91M |
| Working Capital | 12M | 18M | 21M | 17M | 81M | 64M | 57M | 48M | 31M | 58M | 46M | 47M | 45M |
| Current Assets | 15M | 22M | 27M | 23M | 90M | 77M | 66M | 61M | 43M | 70M | 56M | 58M | 55M |
| Current Liabilities | 3.8M | 4.1M | 5.3M | 6.0M | 8.6M | 12M | 9.2M | 13M | 12M | 13M | 11M | 12M | 9.4M |
| Per Share Data | |||||||||||||
| EPS | -1.03 | 0.24 | -0.15 | -0.17 | 1.83 | -0.58 | -0.35 | -0.44 | -0.67 | -0.54 | -0.66 | -0.27 | -0.23 |
| Owner EPS | -0.10 | -0.21 | -0.17 | -0.18 | 0.52 | -0.67 | -0.62 | -0.48 | -0.81 | -0.32 | -0.64 | -0.26 | -0.25 |
| Book Value | 0.09 | 0.67 | 1.00 | 0.74 | 2.54 | 2.10 | 1.87 | 1.56 | 1.09 | 0.77 | 0.40 | 0.35 | 0.31 |
| Cash Flow/Share | -0.02 | -0.17 | -0.11 | -0.12 | 0.61 | -0.54 | -0.47 | -0.30 | -0.59 | -0.15 | -0.51 | -0.19 | -0.20 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 17.7M | 34.9M | 26.3M | 29.8M | 34.3M | 34.0M | 34.0M | 34.5M | 34.6M | 34.7M | 35.5M | 41.5M | 41.9M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -16.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | 3.9 | 3.8 | 8.0 | 1.9 | 3.8 | 4.4 | N/A | 12.8 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 8.2 | 6.9 | 7.8 | 5.0 | 2.7 | 1.2 | N/A | 2.9 |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | -7.1% | -6.9% | -2.6% | -30.3% | -5.7% | -30.3% | N/A | -5.5% |
| Market Cap | 0 | N/A | N/A | N/A | N/A | 280M | 243M | 429M | 70M | 101M | 62M | 0 | 164M |
| Avg. Price | 0.00 | N/A | N/A | N/A | N/A | 6.86 | 5.61 | 11.04 | 6.42 | 3.75 | 1.56 | 0.00 | 3.92 |
| Year-End Price | 0.00 | N/A | N/A | N/A | N/A | 8.23 | 7.15 | 12.44 | 2.03 | 2.67 | 1.64 | 0.00 | 3.92 |
Apyx Medical Corp passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 64.6%.
Apyx Medical Corp (APYX) has a debt-to-equity ratio of 2.70. This indicates higher leverage, which may increase financial risk.
Apyx Medical Corp (APYX) reported earnings per share (EPS) of $-0.27 in its most recent fiscal year.
Apyx Medical Corp (APYX) has a return on equity (ROE) of -78.0%. A negative ROE may indicate losses or negative equity.
Apyx Medical Corp (APYX) has a 5-year average gross margin of 64.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for Apyx Medical Corp (APYX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Apyx Medical Corp (APYX) has a book value per share of $0.35, based on its most recent annual SEC filing.
No recent press releases.